Leaving nothing behind: Is it time to move away from primary stenting in the SFA? (OUS only)


In this supplement: -Femoropopliteal disease: The rationale of leaving nothing behind -Treatment algorithm: How DCB evidence changed my practice -From stents to drug-coated balloons: Is this the time to shift towards a “leave nothing behind” strategy? -Popliteal artery: DAART vs. DCB alone -A tale of two legs: Putting patients ahead by leaving nothing behind